Science and Technology Committee report on the “valley of death”

MRC Technology's CEO, Dave Tapolczay, gave evidence to the UK House of Commons Science and Technology Committee…

MRC Technology and MS Society launch joint ‘Call for Targets’

The call aims to to fast-track the discovery and development of novel drugs to slow, stop or reverse progression in MS or treat MS symptoms. The call to academic researchers seeks to fund further validation of small molecule and antibody targets prior to initiating a full scale drug discovery project to produce ‘drug-like’ molecules or therapeutic antibodies that have the potential to become therapies.

MRC Technology and AICR partnership reports success for cancer research

The partnership enables AICR to take advantage of MRC Technology’s IP management, technology transfer, and drug discovery expertise, to help maximise the health benefits and revenue derived from AICR-funded research. MRC Technology reviewed and monitored 25 priority projects from AICR's portfolio, and negotiated revenue sharing agreements for three of these projects.

MRC Technology forms alliance with world leading translational research centres to accelerate global drug development

Six of the world’s top translational health research centres have come together to form a new Global Alliance of Leading Drug Discovery and Development Centres. The aim of this alliance is to strengthen the international academic and/or not-for-profit drug development and commercialization network to ultimately improve the rate at which academic research is translated into new medicines.

MRC Technology and Chinese Academy of Science collaborate to identify new targets for drug discovery

The collaboration will combine the SIBCB’s research expertise in generating potential new drug targets, with MRC Technology’s experience in further developing early stage research for pharmaceutical application and commercialisation. The focus of the collaboration is to fast track innovative drugable targets to create potent and selective novel therapeutics.

MRC Technology supports Parkinson’s UK through its research grant terms approval service

Parkinson’s UK is the latest medical research funder to benefit from its recently launched research grant terms approval service. As an expert in commercialising intellectual property, MRC Technology is ideally placed to advise on how best to ensure that grant terms and conditions are comprehensive, meet industry standards, and have the best chance of supporting the development of novel treatments.

MRC Technology launches small molecule compound library access scheme

Scheme provides access to a representative subset of 9,000 compounds from 150,000 strong small molecule compound library to academic research institutes free of charge. The scheme has been launched by MRC Technology to provide academics with a high quality compound library for screening, to reduce academic spend on libraries less suited to screening, and to encourage groups to tap into MRC Technology’s drug discovery expertise for research programmes.

Intellect Neurosciences and MRC Technology announce humanization of next-generation monoclonal antibody to amyloid beta with reduced potential for inflammation in the brain of Alzheimer’s patients

MRC Technology and Intellect Neurosciences have completed humanization of 82E1, a mouse monoclonal antibody to create a high-affinity stabilized IgG4 therapeutic antibody that binds the amino terminus of amyloid beta without binding to the amyloid precursor protein (APP). The antibody is anticipated to promote the clearance of monomeric, oligomeric and plaque forms of amyloid beta, which accumulate in the brains of Alzheimer's patients or following traumatic brain injury and in the retina of the eye in patients with age-related macular degeneration, diabetic neuropathy and glaucoma.

New postpartum haemorrhage drug discovery project launched

A collaboration between MRC Technology and Dr Andrew Blanks at the University of Warwick has been launched to develop inhibitors of inwardly rectifying potassium channel kir7.1 for the treatment of postpartum haemorrhage.